Synthesis and Identification of a Novel Lead Targeting Survivin Dimerization for Proteasome-Dependent Degradation by Peery, Robert et al.
Synthesis and identification of a novel lead targeting survivin dimeriza-
tion for proteasome-dependent degradation 
Robert Peery1, Kwaku Kyei-Baffour2, Zizheng Dong1,3, Pedro de Andrade Horn2, Mingji Dai2*, Jing-
Yuan Liu*1,4, Jian-Ting Zhang*1,3 
1Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana 46202 
2Department of Chemistry and Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907; 
3Department of Cancer Biology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio 43614 
4Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio 43614 
KEYWORDS: Survivin, prostate cancer, small-molecule therapy, chemoresistance 
ABSTRACT: Survivin, a homodimeric member of the Inhibitor of Apoptosis Protein (IAP) family, is required for cancer cell 
survival and overexpressed in almost all solid tumors. However, targeting survivin has been challenging due to its “undrug-
gable” nature. Recently, we used a novel approach to target the dimerization interface and identified inhibitors of two scaf-
folds that can directly bind to and inhibit survivin dimerization. One of the scaffolds, represented by the compound LQZ-7, 
contain an undesirable labile hydrazone linker and a potentially non-functional furazanopyrazine ring that we attempted to 
eliminate in this study. We found one compound, 7I, that is more active than the parent compound, LQZ-7, and when given 
orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors. These findings indicate that 7I with a 
stable linker and a quinoxaline ring can be used as a lead for further optimization of this novel class of survivin inhibitors. 
Introduction 
Survivin (BIRC5), a 16.5-kDa homo-di-
meric protein 1, is a member of the Inhibitor of 
Apoptosis Protein (IAP) family with a single 
BIR domain, a zinc-finger fold, and an extended 
C-terminal helical coiled coil 2-4. Ectopic over-
expression of survivin inhibits both intrinsic
and extrinsic apoptosis pathways in cell lines
and animal models, and has been suggested to
contribute to treatment resistance 5-8.  Interest-
ingly, survivin is expressed at undetectable or
low levels in normal adult tissues while it has
been shown to be overexpressed in almost all
solid tumors 9.  Molecular probes such as anti-
sense oligonucleotides, ribozymes, siRNAs, and
dominant negative mutants all resulted in
caspase-dependent cell death and increased
drug-induced apoptosis 10-16. Thus, survivin has
become a significant and attractive drug target
17.
However, survivin has been considered 
‘undruggable’ due to lack of known enzymatic 
activities and the majority of drug discovery 
studies targeting survivin have avoided target-
ing the protein directly 17, 18. Recently, using a 
combination of computational analysis and in 
silico screening, we have identified the first di-
rect small molecule inhibitor of survivin target-
ing the residues of Leu98 and Phe101 in the di-
merization interface of survivin to inhibit sur-
vivin dimerization 19. The initial hit inhibitor, 
LQZ-7, upon binding to the survivin dimeric in-
terface, causes exposure of the hydrophobic di-
merization core and leads to protein misfolding 
and subsequent degradation in proteasome.   
In the current study, we further investi-
gated the scaffold of LQZ-7 and synthesized five 
novel analogues with a goal to improve its 
property and assess whether removal of the 
undesirable labile hydrazone linker and a po-
tentially non-functional furazanopyrazine is 
possible. Of these 5 analogues, one compound 
LQZ-7I (7I)) showed significantly improved ac-
tivity and is the focus of this manuscript. The 
data obtained utilizing 7I in both in-vitro and 
in-vivo studies highlights its potential as a lead 
for further development, which may yield a po-
tential cancer therapeutic by targeting the sur-
vivin protein directly. 
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Figure 1. Analysis of LQZ-7 binding to survivin and synthesis of LQZ-7 
analogues. (A). Molecular dynamic simulation analysis of LQZ-7 bound 
to the dimeric interface of survivin. (B). Critical interactions between 




Design and synthesis of novel LQZ-7 ana-
logs. To investigate the structure-activity rela-
tionship of LQZ-7 for lead identification and 
creation of better and novel survivin inhibitors, 
we first performed molecular dynamic simula-
tion analysis of LQZ-7 bound to the dimeric in-
terface of survivin. As shown in Figure 1A-B, 
LQZ-7 has three important interactions with 
survivin: (a) H-bond between an aniline NH 
group of LQZ-7 and Glu94 of survivin; (b) inter-
action between the substituted aniline in LQZ-
7 and Phe93, Phe101, and Leu98 in the hydro-
phobic pocket of survivin via π-π stacking and 
hydrophobic interaction; and (c) H-bond be-
tween the carboxylic acid of LQZ-7 and Trp10 
of survivin. This analysis shows clearly that the 
furazanopyrazine ring did not contribute to the 
binding to survivin. It is also noteworthy that 
LQZ-7 has a labile hydrazone linker, which is 
undesirable. Thus, for the new synthesis, we at-
tempted to remove the hydrazone linker and to 
replace the furazanopyrazine with a quinoxa-
line ring. To this end, five analogues were syn-
thesized by two nucleophilic aromatic substitu-
tions of dichloroquinoxaline with the corre-
sponding amine and/or amide nucleophiles 
(Figure 1C). All five analogues, LQZ-7G to LQZ-
7K (7G-7K), retain the two predicted critical 
interactions with survivin and have the labile 
hydrazone linker replaced.  
7I has enhanced cytotoxicity compared to 
the parent compound LQZ-7. These five newly 
synthesized LQZ-7 analogs were first tested for 
their cytotoxicity against prostate cancer cell 
lines C4-2 and PC-3 in comparison with their 
parent compound LQZ-7 using methylene blue 
assay. Dose-response survival curves were 
generated following 72-hr treatments (supple-
mental Figure S1), which were used to derive 
their IC50’s. As shown in Figure 2A-B, the ana-
logue 7I has improved cytotoxicity with an IC50 
of 3.1 µM against C4-2 cells and 4.8 µM against 
PC-3 cells compared with the parent compound 
LQZ-7, which has an IC50 of 9.1 and 8.1 µM, re-
spectively. The other compounds performed 
worse with higher IC50 compared with LQZ-7. 
 
Figure 2. Characterization of LQZ-7 analogues. (A-B). IC50 of LQZ-7 and 
its analogues in C4-2 (A) and PC-3 (B) cells derived from dose response 
survival curves (Figure S1) as determined using methylene blue assay. 
(C-D). SEAP reporter activity determined using mammalian two hybrid 
assay in the presence of LQZ-7 or its analogues. Vector and p53:large T 
antigen were used as negative and positive controls for the assay, re-
spectively. (* p<0.05; ** p<0.01; *** p<0.001). 
7I inhibits survivin dimerization. As this 
series of survivin inhibitors were designed to 
exert their action through interaction with the 
dimeric interface and disruption of survivin di-
merization, we next assessed their activity in 
inhibiting survivin dimerization using a mam-
malian two hybrid assay by fusing one survivin 
molecule to the GAL4-DNA-binding domain 
and another to the VP16 activation domain. Di-
merization of survivin activates the expression 
of Secreted Embryonic Alkaline Phosphatase 
(SEAP) reporter gene, which can be monitored. 
As shown in Figure 2C, 7I significantly de-
creased the SEAP reporter expression, while 
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7H slightly inhibited and the other compounds 
did not reduce reporter expression, consistent 
with their limited cytotoxicity against C4-2 and 
PC-3 cells. Thus, 7I was chosen for further stud-
ies.  
 
Figure 3. (A). Relative survivin protein level in different human pros-
tate cancer cell lines determined using Western blot analyses. (B). IC50 
of 7I in different human prostate cancer cell lines derived from dose-
dependent survival curves (Figure S2) as determined using methylene 
blue assay. (C). Association of 7I IC50 with survivin expression level in 
different human prostate cancer cell lines. (D-E). Expression of HA-
tagged survivin determined using Western blot analysis (D) and IC50 of 
7I derived from survival curves (Figure S3) as determined using meth-
ylene blue assay (E) in stable C4-2 clone with overexpression of HA-
tagged survivin (Sur) and vector-transfected (Vec) control cells. 
(***p<0.001). (F). Effect of 7I on the expression of survivin, XIAP, 
CIAP1, and CIAP2 in C4-2 and PC-3 cells as determined using Western 
blot analysis. 
To ensure that the 7I inhibition of sur-
vivin dimerization in the above two hybrid as-
say is specific to survivin and to eliminate any 
potential non-specific effect, we tested the ef-
fect of newly synthesized 7I on the dimeriza-
tion of p53 with the large T antigen using the 
same mammalian two-hybrid assay and by in-
cluding the vector control. As shown in Figure 
2D, both 7I and the parent compound LQZ-7 
significantly inhibited survivin dimerization. 
However, they both had no effect on p53-large 
T antigen dimerization or the basal reporter ex-
pression from vector alone, suggesting that the 
7I inhibition of survivin dimerization may be 
specific. Furthermore, 7I is significantly more 
effective than LQZ-7 in inhibiting survivin di-
merization, consistent with the difference in 
their IC50 against different prostate cancer cell 
lines. These findings also suggest that 7I may 
inhibit cell survival via inhibiting survivin di-
merization. 
Survivin expression level correlates with 
7I IC50 in different prostate cancer cell lines. To 
determine if 7I inhibits cell survival via inhibit-
ing survivin, we performed an association anal-
ysis of survivin expression with 7I IC50 in five 
prostate cancer cell lines.  Figure 3A shows the 
relative survivin level in 5 prostate cancer cell 
lines assessed using Western blot analyses. Fig-
ure 3B shows the IC50 of 7I in these cell lines 
derived from dose-dependent survival curves 
(supplemental Figure S2). Association analy-
sis showed that the IC50 of 7I strongly corre-
lates with the survivin expression level with a 
correlation coefficient R2=0.79 (Figure 3C). 
This finding suggests that the cancer cells with 
higher level of survivin expression are more re-
sistant to 7I and that 7I likely exerts its cytotox-
icity via survivin.   
Survivin overexpression decreases cellu-
lar sensitivity to 7I. To corroborate the above 
findings and to further investigate if 7I inhibi-
tion of cancer cell survival is via survivin, we 
generated a stable C4-2 clone with overexpres-
sion of HA-tagged survivin (Figure 3D) and 
tested the effect of survivin over-expression on 
7I cytotoxicity. As shown in Figure 3E and 
supplemental Figure S3, survivin over-ex-
pression significantly increased cellular re-
sistance to 7I with an IC50 of ~7 µM compared 
with ~2 µM in vector-transfect control clone, 
further supporting the conclusion that 7I likely 
works via inhibiting survivin. 
Selectivity of 7I. As discussed above, 7I 
may selectively inhibit survivin dimerization.  
To ensure 7I is selective to survivin, we tested 
7I's effect on other members of the IAP family 
by taking advantage of its induction of target 
loss (see below). For this purpose, we 
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performed Western blot analysis to determine 
the expression level of other IAPs including 
XIAP, CIAP1, and CIAP2 in addition to survivin 
following 7I treatment in C4-2 and PC-3 cells. 
As shown in Figure 3F, 7I treatment reduced 
the expression of survivin. However, it did not 
reduce the expression of XIAP, CIAP1, and 
CIAP2. Thus, 7I may be selective to its intended 
target survivin. 
 
Figure 4. 7I induces survivin degradation in proteasome. (A). Time 
course of 7I-induced survivin loss in C4-2 and PC-3 cell lines deter-
mined using Western blot analysis. (B-C). Effect of 7I on survivin half-
life. C4-2 and PC-3 cells were pretreated with cycloheximide (CHX) fol-
lowed by chasing for different times in the presence of 7I or DMSO con-
trol. Cells were lysed for Western blot analysis of remaining survivin 
(B) and quantification of gel densities from three independent experi-
ments (C). (D). Effect of proteasome inhibitors MG132 and bortezomib 
on 7I-induced survivin degradation as determined using Western blot 
analysis. Actin was used as a loading control. Quantification was from 
three independent experiments (**p<0.01; ***p<0.001). 
7I induces survivin degradation in a pro-
teasome-dependent manner. Previously, it has 
been shown that the parent compound LQZ-7 
induces survivin degradation via a pro-
teasome-dependent manner by inhibiting sur-
vivin dimerization. Because 7I inhibited sur-
vivin dimerization as shown above, we hypoth-
esized that 7I will also induce survivin degra-
dation. To test this hypothesis, we examined 
survivin expression level in C4-2 and PC-3 cells 
following 7I treatments. As shown in Figure 
4A, 7I treatments induced time-dependent sur-
vivin loss in both cell lines. We next performed 
a cycloheximide-chase experiment following 7I 
treatment to determine the half-life of survivin. 
As shown in Figure 4B-C, 7I treatments re-
duced the half-life of survivin from 2.2 and 2.3 
hrs to 50 and 25 minutes in C4-2 and PC-3 cells, 
respectively. Thus, 7I induces survivin degra-
dation in both cell lines. 
To determine if 7I-induced survivin 
degradation occurs via proteasome, we per-
formed a rescue experiment by pre-treating 
cells using proteasome inhibitors MG132 and 
bortezomib for 1 hour prior to 7I treatment. As 
shown in Figure 4D, both MG132 and borte-
zomib significantly reversed 7I-induced sur-
vivin loss. Thus, 7I likely induces survivin deg-
radation via proteasome. 
 
Figure 5. 7I induction of apoptosis. (A-B). Western blot analysis of 
cleaved caspase 3 in C4-2 (A) and PC-3 (B) cells following 7I treatment. 
Quantifications were from three independent experiments. (C). 7I-in-
duced apoptosis as determined using Annexin V staining in C4-2 and 
PC-3 cells. (*p<0.05; ***p<0.001). 
7I induces apoptosis. As discussed above, 
depleting survivin or inhibiting survivin using 
dominant negative forms of survivin cause 
spontaneous apoptosis in cancer cells and that 
the parent compound LQZ-7 also induces apop-
tosis 20. We, thus, tested if 7I would induce 
apoptosis by inhibiting survivin.  For this pur-
pose, we first performed Western blot analysis 
of cleaved caspase 3 in C4-2 and PC-3 cells fol-
lowing 7I treatments. As shown in Figure 5A-
B, 7I induced cleavage of caspase 3 in a dose de-
pendent manner in both cell lines. We also per-
formed annexin V staining of C4-2 and PC-3 
cells as another indicator of apoptosis follow-
ing 7I treatments. As shown in Figure 5C, 3 µM 
7I induced ~48% and ~39% apoptosis in C4-2 
and PC-3 cells, respectively. 
7I inhibits growth of PC-3 xenograft tu-
mors by inhibiting survivin. We finally deter-
mined 7I’s in-vivo target inhibition and if it is 
active in suppressing tumor growth using a PC-
3 xenograft model.  For in-vivo analysis, 7I was 
dissolved in corn oil for oral administration. As 
shown in Figure 6A, 7I treatment at 100 mg/kg 
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significantly suppressed tumor growth without 
any notable adverse effect on the mice as indi-
cated by lacking changes in body weight (Fig-
ure 6B) and in wet weight of major organs at 
the end of the study (supplemental Figure 
S4).  The xenograft tumors in the 7I-teatment 
group trended to be smaller and pale in color 
than the control group (Figure 6C-D).  Thus, 7I 
may be effective in inhibiting tumor growth 
with little toxicity. 
 
Figure 6. 7I in-vivo efficacy and target inhibition. (A-B). Effect of 7I on 
ectopic xenograft tumor growth and body weight in male NSG mice.  
Solid square, 7I; solid circle: vehicle. C). Gross anatomy of xenograft tu-
mors. (D). Final wet weight of xenograft tumors. (E-F). Western blot 
analysis of in-vivo survivin target inhibition by 7I treatment. (G). Im-
munofluorescence staining of survivin in xenograft tumors. (*p<0.05; 
***p<0.001). 
We finally examined if 7I inhibits the 
survivin target in-vivo in the treatment group 
by performing Western blot and immunofluo-
rescence staining analyses of xenograft tumors. 
As shown in Figure 6E-G, survivin expression 
was drastically reduced in the xenograft tu-
mors of the treatment group compared with 
that of the control group. These findings sug-
gest that 7I inhibits xenograft tumor growth 
possibly by inhibiting survivin dimerization 
and inducing survivin degradation.  
 
Discussion and Conclusion 
 In this study, we synthesized five ana-
logues of LQZ-7 to investigate the possibility of 
eliminating the labile hydrazone and replacing 
the furazanopyrazine with a quinoxaline, re-
sulting in an analogue, 7I, which is more active 
than the parent compound LQZ-7 and soluble 
in corn oil. 7I is also selective to survivin and 
induces apoptosis and survivin degradation in 
a proteasome-dependent manner. As a result, 
7I inhibits cancer cell survival and suppresses 
xenograft tumor growth. 
Of the 5 newly synthesized analogues, 
only 7I shows better activity in inducing sur-
vivin loss and inhibiting cancer cell survival 
compared with the parent compound LQZ-7. 
We presented several lines of evidence that 
strongly support the conclusion that 7I selec-
tively inhibits survivin by inducing survivin 
loss, leading to inhibition of cancer cell sur-
vival, and induction of apoptosis. Thus, 7I un-
likely exerts its actions as a potential PAINS 
molecule. These findings also confirmed our 
previous observation on LQZ-7 in inducing sur-
vivin degradation by potentially binding to the 
dimeric interface of survivin. 
Although the other 4 analogues have 
similar structure as 7I, they do not have activity 
in inhibiting survivin dimerization. Their IC50’s 
against prostate cancer cell lines are also high, 
consistent with their lack of survivin inhibition. 
In our previous study, several commercially 
available analogues of LQZ-7 (LQZ-7A-E) have 
also been studied with variable activities in in-
ducing survivin degradation and in inhibiting 
cancer cell survival 19 (Table 1). It is notewor-
thy that LQZ-7E (7E) is the only compound that 
does not have the benzene ring, which is essen-
tial for the π-π interaction with survivin, and it 
displayed a complete loss of the ability to in-
duce survivin degradation and inhibited cancer 
cell survival with an IC50 of 60 µM. The other 
analogues had variable activities in inducing 
survivin degradation and/or in inhibiting can-
cer cell survival.  
While we do not have enough infor-
mation to dissect a detailed structure-activity 
relationship of these compounds, we feel that 
with the data obtained in this set of experi-
ments we have accomplished the goal of this 
study which was to eliminate the undesirable 
labile hydrazone linker and potentially non-
functional furazanopyrazine ring. Indeed, the 
activity of 7I suggests that the labile hydrazone 
linker and the furazanopyrazine ring of LQZ-7 
are replaceable. This study will serve as a 
proof-of-concept study for future studies con-
tinuing to modify 7I without the labile hydra-
zone linker and furazanopyrazine ring which 
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may lead to identification of more potent com-
pounds. One of the potential modification sites 
include the nitrogen linker predicted to inter-
act with Glu94 of survivin. Converting the nitro-
gen to oxygen may help reveal if the hydrogen 
bonding is important for 7I-survivin interac-
tion. The benzene ring predicted to interact 
with survivin via π-π stacking is another poten-
tial site for further study. We are currently 
working toward this direction.  
Because survivin has been shown to 
contribute to drug resistance by inhibiting 
drug-induced apoptosis 5-8., it will be of interest 
to assess the effectiveness of 7I in combination 
with chemotherapy for synergism in further 
suppression of xenograft tumor growth greater 
than 7I treatment alone. One possible combina-
tion for the castration resistant prostate cancer 
is docetaxel, which is a frontline treatment for 
this disease. Although very challenging it will 
also be of interest to investigate the binding af-
finity of 7I vs survivin dimerization affinity and 
to investigate if 7I inhibits survivin dimeriza-
tion on or off rate. 
Future studies are also warranted to ex-
plore the complex upstream regulatory path-
ways that tightly control survivin expression to 
assess the effectiveness of our inhibitors for 
cancer cells with different genetic back-
grounds. For example, we note a trend that 7I 
cytotoxicity correlates with p53 status in the 
five different prostate cancer cells lines. The 
cell lines with mutant p53 or p53 null (PC-3 and 
DU-145) tend to not only have higher survivin 
expression as one would expect but also higher 
7I IC50. C4-2 and LNCAP with functional p53 
had lower survivin protein levels and lower 7I 
IC50. Interestingly, 22RV-1 cells, which is 
known to have both full and truncated versions 
of p53, behave similar as the cells with mutant 
p53 in this study. Although DNA-damaging 
agents are not the standard of care for castra-
tion resistant prostate cancers, information 
like this may help guide us in what context and 
disease state these survivin inhibitors may be 
most effective. Other upstream regulators of 
survivin, such as STAT3 and NF-κB, and their 
potential relationship with the cytotoxicity of 
our survivin dimerization inhibitors may also 
need to be investigated. 
It is also noteworthy that although cas-
tration resistant prostate cancer was the dis-
ease focus of this study, survivin inhibitors may 
be also developed against other difficult-to-
treat cancers such as glioblastoma since sur-
vivin expression is up-regulated in essentially 
all solid tumors. It is our long-term goal to ex-
pand and apply our knowledge in developing 
this class of unique survivin inhibitors to test 
their effectiveness in other difficult-to-treat 
cancers.   
In a previous publication 19, we detailed 
the discovery of another LQZ-7 analogue, LQZ-
7F (7F). The interesting feature of 7F compared 
to LQZ-7 and 7I is that it was the only com-
pound identified in any of our screenings that 
had a different backbone scaffold. This com-
pound displayed a locked backbone confor-
mation consisting of 2 five-member rings and 
two-six member rings that maintained key in-
teractions with survivin including (a) H-bond 
between the primary amine group of 7F and 
Glu94 of survivin; (b) π–π stacking and hydro-
phobic interaction between the tetracyclic 
furazanopyrazine ring of 7F and the hydropho-
bic residues Trp10 and Phe93 in addition to the 
dimerization core residues Leu98 and Phe101. 7F 
displayed more potent inhibition of cancer cells 
and had a strong positive correlation between 
survivin expression and cytotoxicity in cancer 
cell lines. More importantly, in an in-vivo xeno-
graft model, 7F treatment via i.p. injection sig-
nificantly inhibited the growth of xenograft tu-
mors 19. 
In conclusion, there are two structural 
scaffolds of inhibitors targeting the dimeriza-
tion interface of survivin, represented by 7F 
and 7I, which effectively inhibit survivin dimer-
ization, induce survivin degradation in pro-
teasome, and induce apoptosis of prostate can-
cer cells. They both also effectively inhibit xen-
ograft tumor growth and reduce survivin level 
in vivo. Thus, both 7F and 7I can be used as 
leads of different scaffolds for further optimiza-
tion.  
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Materials. Antibodies against HA tag 
(H6908) and actin (A5316) and the Annexin V-
FITC apoptosis detection kit were obtained 
from MilliporeSigma. The antibody against sur-
vivin (2808) and the Metafectene Pro transfec-
tion reagent were purchased from Cell Signal-
ing Technology and Bion-tex, respectively. The 
enhanced chemiluminescence reagent was 
from GE Healthcare. The matchmaker mamma-
lian two hybrid assay kit and the Great Escape 
SEAP Chemiluminescence assay kit were pur-
chased from Clontech. Cell culture media and 
fetal bovine serum were from Corning and Ap-
plied Biosystems-Life Technologies, respec-
tively. All other chemicals were purchased 
from Sigma or Fisher Scientific.   
Cell lines. The human prostate cancer 
cell lines C4-2, PC-3, Du145, LNCAP, and 22Rv1 
were purchased from and authenticated by 
ATCC (Manassas, VA). All cell lines were main-
tained at 37°C in 5% CO2 and grown in RPMI 
with 10% fetal bovine serum.  
To generate C4-2 cells with stable ex-
pression of HA-tagged survivin, 2×106 cells 
were plated in a 10-cm dish and transfected 
with 10 µg pcDNA3.1 vector control or HA-
survivin cDNA cloned in pcDNA3.1 vector  us-
ing metafectene pro (Biontex, Munchen, Ger-
many) as we previously described 19. At 48 
hours after transfection, cells were harvested 
and re-plated in a fresh 10-cm dish at 2×105 
cells/dish followed by selection using 0.8 
mg/ml G418 with media and G418 changed 
every 72 hours till colonies are visible for clon-
ing. The stable clones were maintained with 0.2 
mg/ml G418.  
Construct engineering. For the mamma-
lian two hybrid assay, we engineered two con-
structs encoding GAL4-survivin and VP16-
survivin fusion proteins using pBIND and pACT 
vectors, respectively, in the ClonTech Match-
maker Mammalian Two Hybrid Assay kit 21 as 
instructed by the manufacturer. Briefly, the 
cDNA encoding the open reading frame of sur-
vivin was amplified by PCR using primers 5’-
AAGAATTCGGCGGCGGCGGCGGCGATGGGTGCC
CCGACGTTGCCC-3’ (forward) and  
5’-
AACTCGAGTCAATCCATGGCAGCCAGCTGCTC-
3’ (reverse) and cloned into pGEM-T easy vec-
tor (Promega). The resulting plasmid was then 
digested by Eco RI, blunt ended, and digested 
again using Xho I to release the PCR insert, 
which were then cloned into pBIND and pACT 
digested by Bam H1, blunt-ended, and then di-
gested by Sal1. The resulting plasmids pBIND-
survivin and pACT-survivin were validated by 
sequencing.   
Survivin mammalian two hybrid assay. 
The mammalian two hybrid assay was per-
formed using the ClonTech Matchmaker Mam-
malian Two Hybrid Assay kit with the two 
newly engineered fusion plasmids as described 
above. Briefly, DU145 cells were seeded in 12-
well plates at 1×105 cells/well and cultured for 
24 hrs followed by transfection using pBIND-
survivin and pACT-survivin (0.45 µg/well) 
along with the pGSEAP reporter plasmid (0.09 
µg/well) and firefly luciferase reporter plasmid 
(30 ng/well). Two days after transfection,  me-
dia was changed and cells were treated with 
DMSO, LQZ-7  or its analogues for 24 hours fol-
lowed by determination of SEAP activity using 
the Takara ClonTech SEAP Great Escape chem-
iluminescence assay kit 2.0. Luciferase activity 
was also measured as a control for transfection 
efficiency.   
Methylene blue survival assay. The meth-
ylene blue survival assay was performed as 
previously described 22. Briefly, Prostate can-
cer cells were seeded 2000-3500 per well and 
treated with various concentrations of LQZ-7 
and its analogues for 72 hours. After 72 hours, 
media was then removed and cells were fixed 
with methanol for 30 minutes and subse-
quently stained with 100 µL of 1% methylene 
blue (diluted in 10 mM borate buffer) for 1 
hour.  The cells were then washed 3 times with 
10 mM borate buffer and then allowed to air 
dry for 30 minutes. 100 µL of 100% ethanol:0.1 
M HCl (1:1) was added to each well to dissolve 
the methylene blue stain and OD650 nm was 
measured. The data were analyzed using 
GraphPad Prism software to generate fitted 
curves and IC50.    
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Survivin Half-Life Determination. The ef-
fect of 7I on survivin half-life was performed as 
previously described 19, 23. Briefly, PC-3 or C4-2 
cells were pretreated with 10 µM cyclo-
heximide for 1 hour followed by incubation 
with or without 10 µM 7I for different times (0-
6 hours).  The cells were then harvested for 
Western Blot analysis of survivin. 
Annexin V Apoptosis Assay. The apopto-
sis assay was performed as detailed in the An-
nexin V-FITC kit from BioVision.  Briefly, cells 
were treated with 3 µM 7I or DMSO control for 
48 hours followed by harvest, washing, and 
staining with annexin V-FITC antibody and pro-
pidium iodide. The stained cells were then ana-
lyzed using flow cytometry with excitation at 
488 nm and 530 nm.  
In-vivo efficacy. In-vivo studies using an-
imals were approved by IACUC at Indiana Uni-
versity School of Medicine. For the in-vivo effi-
cacy study, 3×106 PC-3 cells in media were im-
planted in the hind flanks of 6-week old NSG 
male mice.  After the tumor volume reached ap-
proximately 100 mm3 in volume, the mice were 
randomized into two groups (5 mice/group).  
The mice were either given 200 µL vehicle 
(90% corn oil/10% DMSO) or 7I (100 mg/kg) 
via oral gavage every other day for a total of ten 
treatments.  The bodyweight and tumor size 
were measured every two days. At the end of 
the study mice were sacrificed, and tumors 
were excised for Western blot and IHC analysis 
of survivin expression. 
Statistical Analysis. All statistical analy-
sis was performed using the program 
GraphPad Prism. Three independent experi-
ments were performed for each study. Data 
presented is the mean ± standard deviation un-
less otherwise noted. All p-values were calcu-
lated using the Prism program via student t 
tests or one-way ANOVA followed by post-hoc 
test depending on the number of groups being 
compared. 
Chemical Synthesis and Methods. To ac-
cess the quinoxaline diamine derivatives (7I), 
(7J), and (7K), commercially available 1,4-di-
hydro-2,3-quinoxalinedione (1, Figure 1C) 
was used as the starting point. Treating 1,4-di-
hydro-2,3-quinoxalinedione (1) with 4-
fluoroaniline (2) or 2,3-dimethyl aniline (3) in 
reflux ethanol afforded 7I and 7J, respectively. 
When 4-tert-butyl aniline (4) was used, the re-
action needed to be heated in DMSO to give the 
desired product 7K. When a 1:1 mixture of 2,3-
quinoxalinedione (1) and 4-fluoroaniline (2) 
was treated with AlCl3 in DCE at an elevated 
temperature, mono-substituted product 5 was 
obtained, which further underwent another 
nucleophilic substitution with either 6a or 6b 
to afford 7G and 7H, respectively. 
All chemical reactions were performed 
using standard syringe techniques under ar-
gon. Starting materials and reagents were used 
as received from commercial suppliers. Ace-
tonitrile (CH3CN), methanol (MeOH), and tolu-
ene were purified by passing the previously de-
gassed solvents through activated alumina col-
umns. Dichloromethane (CH2Cl2) and tetrahy-
drofuran (THF) were distilled prior to use.  
All compounds were purified using flash 
chromatography with silica gel (230-400 
mesh). Thin layer chromatography (TLC) was 
performed using glass-backed silica plates 
(Silicycle). NMR spectra were recorded on a 
Bruker ARX-400 spectrometer or AV-500 spec-
trometer at room temperature. Chemical shifts 
δ (in ppm) are given in reference to the solvent 
signal. 1H NMR data are reported as follows: 
chemical shifts (δ ppm), multiplicity (s = sin-
glet, d = doublet, t = triplet, q = quartet, quin = 
quintuplet, m = multiplet, br = broad), coupling 
constant (Hz), and integration. 13C NMR data 
are reported in terms of chemical shift and mul-
tiplicity. IR data were recorded on a Thermo Ni-
colet Nexus 470 FTIR. Electronspray ionization 
mass spectrometry data for compound charac-
terization were determined using an Advion 
Expression CMS instrument. The purity was 
confirmed to be >95% using Waters ACQUITY 
UPC2 system. 
General procedure for the synthesis of 
quinoxaline amine (5). To a flame-dried round-
bottom flask charged with a stir bar, commer-
cially available 2,3-dichloroquinoxaline (1) 
(170 mg, 0.85 mmol, 1.0 equiv), 4-fluoroaniline 
(2) (0.081 mL, 0.85 mmol, 1.0 equiv.), AlCl3 
(125.3 mg, 0.94 mmol, 1.1 equiv), and DCE 
(4.25 mL, 0.2M) were added sequentially. The 
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reaction mixture was then stirred at 80 oC for 
16 hours. After this period, the reaction was 
cooled to room temperature and quenched 
with ice-cold water (10 mL) while stirring. Stir-
ring was continued for an additional 10 
minutes. The reaction was then extracted with 
EtOAc (3x), and the combined organic layers 
washed with ice-cold water 2x. The organics 
were then dried over MgSO4, filtered, and con-
centrated under reduced pressure. The crude 
product was purified by column chromatog-
raphy using Hexanes - EtOAc (49:1 to 20:1) to 
give the pure product as a yellow solid. Yield: 
92.2 mg, 40%. All spectroscopic data matched 
that previously reported in the literature.1 
General procedure for the synthesis of 
quinoxaline amine carboxamides 7G and 7H 
from intermediate (5). To a suspension of NaH 
(60% in mineral oil, 14.4 mg, 0.36 mmol, 2.0 
equiv) in 0.8 mL of DMF was added the desired 
benzamide (0.36 mmol, 2.0 equiv) The reaction 
mixture was stirred at room temperature for 1 
hour. After the suspension turned lightly yel-
low, 3-chloro-N-(4-fluorophenyl)quinoxalin-2-
amine (5) (50 mg, 0.18 mmol, 1.0 equiv.) in 
DMF (0.2 mL) was added slowly and the solu-
tion turned dark red instantly. The reaction 
mixture was then stirred at 150 oC for 4 hours, 
and then cooled to room temperature before it 
was quenched with ice-cold water (3 mL). The 
reaction mixture was then extracted with 
EtOAc (3x) and the combined organic layers 
were dried over anhydrous MgSO4, and concen-
trated under reduced pressure. The crude 
product was then purified by column chroma-
tography to give a bright yellow solid.  
N-(3-((4-fluorophenyl)amino)quinoxa-
lin-2-yl)benzo[d][1,3]dioxole-5-carboxamide 
(7G). Analog 7G was synthesized from corre-
sponding intermediate (5) (Yellow solid, 5% 
yield). 1H NMR (500 MHz, CDCl3): δ = 9.04 (s, 
1H),  8.01 – 7.94 (m, 3H), 7.77 (d, J = 1.6 Hz, 1H), 
7.71 (d, J = 8.0 Hz, 1H), 7.42 (ddd, J = 8.3, 6.6, 
2.1Hz, 1H), 7.38 – 7.31 (m, 2H), 7.14 (t, J = 8.7 
Hz, 2H), 6.93 (d, J =8.2 Hz, 1H), 6.09 (s, 2H); 13C 
NMR: (125 MHz, CDCl3): δ = 179.12, 159.85, 
157.92, 151.43, 147.84, 145.96, 145.19, 135.15, 
134.81, 131.33, 126.66, 126.59, 125.90, 125.22, 
124.75, 121.23, 116.84, 115.81, 115.63, 109.30, 
107.95, 101.78; IR (neat, cm-1): ν = 3319, 2921, 
1593, 1546, 1506, 1483, 1437, 1382, 1356, 
1292, 1255, 1209, 1192, 1156, 1104, 1038, 926, 
832, 808. MS (ESI): m/z 403.1 found for 
C22H16FN4O3[M+H]+. 
N-(3-((4-fluorophenyl)amino)quinoxa-
lin-2-yl)benzamide (7H). Analog 7H was syn-
thesized from corresponding intermediate (5) 
(Yellow solid, 58% yield). 1H NMR (500 MHz, 
CDCl3):  δ = 9.06 (s, 1H), 8.30 (d, J = 7.5 Hz, 2H), 
7.98 – 7.89 (m, 2H), 7.98 – 7.89 (m, 1H), 7.61 – 
7.55 (m, 1H), 7.51 (t, J = 7.5 Hz, 2H), 7.43 – 7.37 
(m, 1H), 7.35 – 7.27 (m, 1H), 7.11 (t, J = 8.5 Hz, 
2H); 13C NMR: (125 MHz, CDCl3): δ = 180.15, 
159.91, 157.98, 146.00, 145.41, 136.90, 135.37, 
134.95, 132.64, 129.44, 128.48 (2C), 126.80, 
126.76, 126.00, 124.72, 121.20, 121.14, 117.01, 
115.89, 115.71. IR (neat, cm-1): ν = 3316, 3066, 
1592, 1551, 1506, 1483, 1448, 1413, 1385, 
1356, 1314, 1291, 1210, 1156, 1124, 1100, 
1068, 1024, 921, 864, 831. MS (ESI): m/z 359.2 
found for C21H16FN4O[M+H]+. 
General procedures for the synthesis of 
quinoxaline-2,3-diamines (7I) and (7J). To a 
flame dried round bottomed flask, commer-
cially available 2,3-dichloroquinoxaline (1) 
(200 mg, 1.0 mmol, 1.0 equiv.), substituted ani-
lines (2 or 3) (2.2 mmol, 2.2 equiv.), and etha-
nol (5.0 mL, 0.2M) are added sequentially. The 
reaction mixture is then refluxed for 16 hours. 
After reaching room temperature, the solvent 
was slowly removed under reduced pressure. 
The resulting solid is dissolved in EtOAc (10 
mL), washed with water and brine, dried over 
anhydrous MgSO4 and concentrated under re-
duced pressure to give the crude product. The 
crude product was then purified by column 
chromatography. 
General procedures for the synthesis of 
quinoxaline-2,3-diamine (7K). A mixture of 2,3-
dichloroquinoxaline (1) (50 mg, 0.25 mmol, 1.0 
equiv.), 4-tert-Butylaniline (4) (1.25 mmol, 5.0 
equiv.) and DMSO (2.5 mL, 0.1M) in a flame 
dried round-bottomed flask was heated at 130 
°C for 2.5 hours. After this period, the reaction 
mixture is cooled to room temperature and di-
luted with EtOAc (2.5 mL) and poured into ice-
water (10 mL). The organic phase is then 
washed with ice-cold water 2x and dried over 
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MgSO4, and concentrated under reduced pres-
sure. The crude product was then purified by 
column chromatography using Hexanes: EtOAc 
(20:1) to give the pure product. 
N2,N3-bis(4-fluorophenyl)quinoxaline-
2,3-diamine (7I). Analog 7I was synthesized us-
ing method A from commercially available (1) 
and 4-Fluoroaniline (2). Column chromatog-
raphy was performed using a Hexanes:EtOAc 
(20:1 to 3:1) mixture to give the pure product. 
(Yellow solid, 52% yield). 1H NMR (500 MHz, 
DMSO-d6): ):  δ = 9.06 (s, 2H), 7.95-7.75 (m, 4H), 
7.53 (dd, J = 6.1, 3.5 Hz, 2H), 7.33 (dd, J = 6.1, 
3.4 Hz, 2H), 7.24 (t, J = 8.9 Hz, 4H). 13C NMR 
(125 MHz, DMSO-d6): δ = 158.74 (2C), 156.84 
(2C), 141.19, 141.16, 136.49, 136.13, 125.34, 
125.15, 125.11, 122.37, 122.31, 115.29 (2C), 
115.26 (2C), 115.11, 115.09 (2C). IR (neat, cm-
1): ν = 3386, 2925, 1644, 1616, 1574, 1537, 
1501, 1449, 1410, 1328, 1301, 1212, 1155, 
1118, 1098, 1012, 923, 830. MS (ESI): m/z 
349.2 found for C20H15F2N4[M+H]+. 
N2,N3-bis(2,3-dimethylphenyl)quinoxa-
line-2,3-diamine (7J). Analog 7J was synthe-
sized using method A from commercially avail-
able (1) and 2,3-Dimethylaniline (3). Column 
chromatography was performed using a Hex-
anes:EtOAc (49:1 to 20:1) mixture to give the 
pure product. (Light brown solid, 16% yield). 
1H NMR (500 MHz, DMSO-d6): δ = 8.52 (s, 2H), 
7.38-7.23 (m, 4H), 7.22-7.12 (m, 4H), 7.09 (d, J 
= 7.6 Hz, 2H), 2.32 (s, 6H), 2.11 (s, 6H). 13C NMR 
(125 MHz, DMSO-d6): δ 142.59 (2C), 137.72 
(2C), 137.15 (2C), 136.62 (2C), 132.27 (2C), 
126.88 (2C), 125.47 (2C), 125.05 (2C), 124.30 
(2C), 124.16 (2C), 20.29 (2C), 14.56 (2C). IR 
(neat, cm-1): ν = 3312, 2916, 1640, 1614, 1567, 
1541, 1463, 1381, 1351, 1324, 1258, 1215, 
1181, 1119, 1089, 1060, 990, 927, 896, 779. MS 
(ESI): m/z 369.2 found for C24H25N4[M+H]+. 
N2,N 3-bis(4-(tert-butyl)phenyl)quinox-
aline-2,3-diamine (7K). Analog 7K was synthe-
sized using method B from commercially avail-
able (1) and 4-tert-Butylaniline (4). Column 
chromatography was performed using a Hex-
anes:EtOAc (20:1) mixture to give the pure 
product. (Light brown oil, 23% yield). 1H NMR 
(500 MHz, DMSO-d6): δ = 8.97 (s, 2H), 7.82 (d, J 
= 8.7 Hz, 4H), 7.52 (dd, J = 6.1, 3.4 Hz, 2H), 7.42 
(d, J = 8.7 Hz, 4H), 7.32 (dd, J = 6.1, 3.4 Hz, 2H), 
1.32 (s, 18H). 13C NMR (125 MHz, DMSO-d6): δ 
144.96 (2C), 141.12 (2), 137.55 (2C), 136.19 
(2C), 125.24 (4C), 124.93 (4C), 120.35 (4C), 
34.06 (2C), 31.31 (6C). IR (neat, cm-1): ν = 3385, 
2958, 2902, 2865, 1640, 1613, 1586, 1570, 
1513, 1450, 1408, 1361, 1330, 1315, 1294, 
1266, 1245, 1191, 1144, 1111, 1016, 940, 858, 
831. MS (ESI): m/z 425.3 found for 
C28H33N4[M+H]+. 
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aThe data for LQZ-7A-E were from the previous study 19. The IC50 was determined using MTT assay. 
bThe data for LQZ-7G-K were from this study. The IC50 was determined using methylene blue assay. 
cND=not determined. 
  


















 ND - 
LQZ-7Ba 
 3.3±0.2 
 ND + 
LQZ-7Ca 
 3.5±0.0 
 ND + 
LQZ-7Da 
 2.6±0.3 
 ND - 
LQZ-7Ea 
 60.3±1.0 
 ND - 
LQZ-7Gb 
 20.7± 2.0 14.3±1.4 
- ND 
LQZ-7Hb 
 19.7±0.4 12.7±1.7 
- ND 
LQZ-7Ib 
 4.8±0.1 3.1±0.2 
+ + 
LQZ-7Jb 
 24.8±1.8 17.6±3.4 
- ND 
LQZ-7Kb 
 18.2±0.2 18.6±0.9 
- ND 
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